Stay updated on MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety
Sign up to get notified when there's something new on the MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety page.

Latest updates to the MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedCore study content appears unchanged; the screenshots show only superficial UI adjustments with no updates to the Brief Summary, Eligibility Criteria, Interventions, outcomes, or key dates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check33 days agoChange DetectedUpdate includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. The core effect is informing users about possible delays and the current open status of the NIH Clinical Center.SummaryDifference3%

- Check40 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%

- Check54 days agoChange DetectedUpdated page from v3.0.1 to v3.0.2 with no substantive content changes; removal of 'Back to Top' is a minor navigation tweak.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page has been updated to reflect a new version of a study on tildrakizumab, with a change in the publication date and version number.SummaryDifference0.4%

- Check69 days agoChange DetectedThe web page has added significant information regarding the facility name, location, and drug information related to Tildrakizumab, while removing various location details and resources related to psoriasis and other skin diseases.SummaryDifference3%

Stay in the know with updates to MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety
Enter your email address, and we'll notify you when there's something new on the MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety page.